Progression and complications after external beam radiation therapy for carcinoma of prostate

Urology. 1989 Sep;34(3):115-9. doi: 10.1016/0090-4295(89)90242-2.

Abstract

Sixty patients with prostatic carcinoma localized to the pelvis have been treated by external beam radiation therapy: 2 patients (2%) were Stage A, 12 (20%) Stage B, 14 (23%) Stage C, and 32 (53%) Stage D1. Twenty-two patients received adjuvant therapy (11 estramustine phosphate [Estracyt] and 11 cyclophosphamide [Cytoxan]) after radiation. Progression occurred in 22 patients (37%): 6 (10%) had local recurrence while 16 (27%) failed distally. The incidence of late major complications was 12 percent.

MeSH terms

  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / radiotherapy*
  • Cobalt Radioisotopes / therapeutic use*
  • Combined Modality Therapy
  • Cyclophosphamide / therapeutic use
  • Estramustine / therapeutic use
  • Humans
  • Lymph Node Excision
  • Lymphatic Metastasis
  • Male
  • Middle Aged
  • Prostatic Neoplasms / drug therapy
  • Prostatic Neoplasms / radiotherapy*
  • Radioisotope Teletherapy* / adverse effects
  • Radiotherapy, High-Energy* / adverse effects

Substances

  • Cobalt Radioisotopes
  • Estramustine
  • Cyclophosphamide